"Experimental Hematology" UCM-Research Group, Veterinary Faculty, Complutense University of Madrid, Avda Puerta de Hierro s/n, 28040, Madrid, Spain.
Department of Biochemistry and Molecular Biology, Veterinary Faculty, Complutense University of Madrid, Avda Puerta de Hierro s/n, 28040, Madrid, Spain.
Stem Cell Res Ther. 2020 Jun 29;11(1):261. doi: 10.1186/s13287-020-01778-5.
Wound healing is a complex biological process comprised of a series of sequential events aiming to repair injured tissue. Adult mesenchymal stem cells (MSCs) have been used in cellular therapy in preclinical animal studies; a promising source of MSCs is adipose tissue (AT). In this paper, we evaluated the clinical value and safety of the application of cultured allogenic MSCs from AT for acute and chronic skin wound healing in a canine model.
Twenty-four dogs of different breeds between 1 and 10 years of age with acute and chronic wounds were studied. Morphology of the wounded skin was monitored for changes over time via serial photographs and histopathological studies.
The percentage of the wounds that exhibited contraction and re-epithelialization were significantly different between wounds treated with adipose mesenchymal stem cells (ASCs) and control wounds; this effect was observed in both acute and chronic conditions. At 90 days, re-epithelization of acute and chronic wounds reached more than 97%. Histopathological study revealed a reduction in inflammatory infiltrate and the presence of multiple hair follicles on day 7 after treatment with ASCs, promoting epidermal and dermal regeneration. To guarantee the safety of our treatment, we determined the serum levels of cytokine markers in our patients. ASC treatment upregulated granulocyte-macrophage colony stimulating factor (GM-CSF) at the gene level, which may contribute to the recruitment of cells that participate in skin repair to the site of injury.
The development of an allogenic ASC therapy to improve wound healing in a canine model could have a clinical impact in human treatment.
伤口愈合是一个复杂的生物学过程,由一系列旨在修复受损组织的连续事件组成。成体间充质干细胞(MSCs)已在临床前动物研究中用于细胞治疗;脂肪组织(AT)是 MSCs 的有前途来源。在本文中,我们评估了应用源自 AT 的培养同种异体 MSCs 治疗犬模型中急性和慢性皮肤伤口愈合的临床价值和安全性。
研究了 24 只不同品种的 1 至 10 岁的犬,这些犬患有急性和慢性伤口。通过定期拍摄照片和组织病理学研究监测受伤皮肤的形态变化,以评估伤口愈合情况。
用脂肪间充质干细胞(ASCs)治疗的伤口与对照伤口相比,收缩和再上皮化的伤口百分比有显著差异;这种效果在急性和慢性情况下都观察到。在 90 天时,急性和慢性伤口的再上皮化达到了 97%以上。组织病理学研究显示,在治疗后第 7 天,炎症浸润减少,存在多个毛囊,促进了表皮和真皮的再生。为了保证我们治疗的安全性,我们测定了患者的细胞因子标志物血清水平。ASC 治疗上调了粒细胞-巨噬细胞集落刺激因子(GM-CSF)的基因水平,这可能有助于募集参与皮肤修复的细胞到损伤部位。
开发用于改善犬模型伤口愈合的同种异体 ASC 疗法可能会对人类治疗产生临床影响。